GT200500049A - Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso para tratar la diabetes y trastornos relacionados - Google Patents

Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso para tratar la diabetes y trastornos relacionados

Info

Publication number
GT200500049A
GT200500049A GT200500049A GT200500049A GT200500049A GT 200500049 A GT200500049 A GT 200500049A GT 200500049 A GT200500049 A GT 200500049A GT 200500049 A GT200500049 A GT 200500049A GT 200500049 A GT200500049 A GT 200500049A
Authority
GT
Guatemala
Prior art keywords
naftiridine
derivatives
diabetes
related disorders
treat diabetes
Prior art date
Application number
GT200500049A
Other languages
English (en)
Spanish (es)
Inventor
Rainer Heurich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500049A publication Critical patent/GT200500049A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GT200500049A 2004-03-12 2005-03-11 Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso para tratar la diabetes y trastornos relacionados GT200500049A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55297104P 2004-03-12 2004-03-12

Publications (1)

Publication Number Publication Date
GT200500049A true GT200500049A (es) 2005-10-24

Family

ID=35056657

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500049A GT200500049A (es) 2004-03-12 2005-03-11 Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso para tratar la diabetes y trastornos relacionados

Country Status (6)

Country Link
AR (1) AR048088A1 (zh)
GT (1) GT200500049A (zh)
PE (1) PE20060332A1 (zh)
TW (1) TW200538124A (zh)
UY (1) UY28805A1 (zh)
WO (1) WO2005091857A2 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015917A2 (en) * 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CA2839395A1 (en) 2011-07-12 2013-01-17 F. Hoffmann-La Roche Ag Aminomethyl quinolone compounds
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
TWI748941B (zh) 2015-02-27 2021-12-11 美商英塞特公司 Ｐｉ３ｋ抑制劑之鹽及製備方法
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2018102885A1 (en) * 2016-12-09 2018-06-14 Bionomics Limited Modulators of nicotinic acetylcholine receptors and uses thereof
JOP20180097B1 (ar) * 2018-10-22 2023-03-28 Univ Of Jordan مشتقات 1.8 - نفثاريدين الغلايكوزيلية و طرق تحضيرها و استخدامها في معالجة الالتهابات الميكروبية

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL51092A0 (en) * 1976-12-10 1977-02-28 Abic Ltd Naphthyridine derivatives and their preparation
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials

Also Published As

Publication number Publication date
WO2005091857A2 (en) 2005-10-06
AR048088A1 (es) 2006-03-29
PE20060332A1 (es) 2006-06-01
WO2005091857A3 (en) 2006-10-05
TW200538124A (en) 2005-12-01
UY28805A1 (es) 2005-09-30

Similar Documents

Publication Publication Date Title
GT200500049A (es) Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso para tratar la diabetes y trastornos relacionados
CL2008000212A1 (es) Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre
GT200600197A (es) Compuestos y composiciones como inhibidores de proteina quinasa
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
GT200600167A (es) Derivados de dihidrobenzofurano y usos de los mismos
BRPI0411528A (pt) uso de isomalte como prebiótico
CR10852A (es) Compuestos biciclicos y su uso como anti-diabeticos
GT200600011A (es) Procedimientos para preparar eteres de pirazolo [3,4-d] pirimidina
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
ATE526331T1 (de) Pyrrolopyrimidine für pharmazeutische zusammensetzungen
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
GT200500208A (es) Indazoles ùtiles para tratar enfermedades cardiovasculares
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
CR10401A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
GT200300219A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
UY32312A (es) 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2
MY143241A (en) 3, 5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
CR10682A (es) Compuestos de tiazol pirazolopirimidina
EA200801220A1 (ru) 3-аминоциклопентанекарбоксамиды в качестве модуляторов хемокиновых рецепторов
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
CO6470792A2 (es) Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
GT200600336A (es) Moduladores del receptor de progesterona cianopirrol-sulfonamida y usos de los mismos